ATH 13.7% 4.4¢ alterity therapeutics limited

PBT519 -Development

  1. 1,847 Posts.
    lightbulb Created with Sketch. 1
    While we are at it here is some information on PBT519 for brain cancer-

    PBT519 treatment resulted in a dose-related tumor area reduction in C6 (16%) and SMA560 (60 and 60%) in mouse glioma models for the 100 mg dose.

    Additionally PBT519 was tested in preclinical studies on humans in the Netherlands with 65 healthy human particpants at single and multiple doses up to 800 mg. The studies determined that PBT519 was safe and well tolerated at doses up to 800 mg.
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
(20min delay)
Mkt cap ! $37.87M
Open High Low Value Volume
4.6¢ 4.6¢ 4.4¢ $10.3K 225K

Buyers (Bids)

No. Vol. Price($)
1 15000 4.4¢

Sellers (Offers)

Price($) Vol. No.
5.1¢ 120020 2
View Market Depth
Last update - 15.58pm 19/04/2019 (20 minute delay) ?
ATH (ASX) Chart
GET SUPPORT arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.